Key clinical point: A novel diagnostic panel has high performance for distinguishing eosinophilic gastritis (EG) patients from non-EG controls.
Major finding: The EGDP18 score identified active EG patients in both cohorts (P less than .0001, AUC equal to or greater than 0.95).
Study details: A molecular analysis of 18 genes highly dysregulated in EG.
Disclosures: The researchers reported having no financial disclosures.
Shoda T et al. DDW 2019, Abstract 165. doi: 10.1016/S0016-5085(19)36878-7.